Arthritis Patents (Class 514/825)
-
Patent number: 6120804Abstract: Topical gelled compositions comprising an optional drug dispersed within a polymer matrix, methods of producing the same and treatments with the complex.Type: GrantFiled: April 8, 1999Date of Patent: September 19, 2000Assignee: L.A.M. Pharmaceuticals LLCInventors: Alan Drizen, Peter Rothbart, Gary M. Nath
-
Patent number: 6107334Abstract: The present invention is directed towards the control of inflammation. More specifically there are provided herein dietary fatty acid regimens that may be used to inhibit the increase of serum arachidonic acid when GLA is provided as a dietary supplement.Type: GrantFiled: February 23, 1998Date of Patent: August 22, 2000Assignee: Wake Forest UniversityInventor: Floyd H. Chilton
-
Patent number: 6090852Abstract: Compounds of formula (I): ##STR1## where the substituents are as defined herein, and salts thereof, are matrix metalloprotease inhibitors.Type: GrantFiled: January 20, 1999Date of Patent: July 18, 2000Assignee: Pfizer IncInventors: Kevin Neil Dack, Gavin Alistair Whitlock
-
Patent number: 6083521Abstract: This invention provides pharmaceutical compositions comprising polymeric matrices, especially those comprising IL-6 as an active ingredient. Specific novel poly(ethylene carbomate) polymers are also provided for more general use as matrix materials in sustained release compositions containing pharmacologically active compounds, as are methods of using of IL-6 for treatment of conditions mediated by IL-1 and/or TNF.alpha., e.g., certain autoimmune and inflammatory conditions, as well as septic shock.Type: GrantFiled: September 28, 1998Date of Patent: July 4, 2000Assignee: Novartis AGInventors: Murat Acemoglu, Siegfried Bantle, David Bodmer, Salvatore Cammisuli, Peter Hiestand, Fritz Nimmerfall, Georg Stoll
-
Patent number: 6083534Abstract: A controlled release pharmaceutical composition includes a biocompatible polymeric material, preferably polyethylene-vinyl acetate or poly(lactic-glucolic acid), having incorporated therein a soluble receptor capable of binding to its ligand and thus affecting the ligand's function. The soluble receptor is preferably the soluble form of TNF.alpha. receptor. Such compositions are for use in the treatment of disorders in which neutralization of the deleterious effects of TNF.alpha. is required.Type: GrantFiled: October 9, 1997Date of Patent: July 4, 2000Assignees: Yeda Research and Development Co. Ltd., Ben-Gurion University of the NegevInventors: David Wallach, Josef Kost, Rom Eliaz
-
Patent number: 6083503Abstract: A method for the treatment or prevention of autoimmune diseases, allergic or atopic disorders, and graft rejection is provided, comprising inducing the death by apoptosis of a subpopulation of T lymphocytes that is capable of causing such diseases, while leaving substantially unaffected the majority of other T lymphocytes. Cell death is achieved by cycle(s) comprising challenging via immunization these T cells with antigenic substance at short time intervals, or by immunization followed by administering interleukin-2 (IL-2) when these T cells are expressing high levels of IL-2 receptor so as to cause these T cells to undergo apoptosis upon re-immunization with the antigenic peptide or protein. These methods are applicable to the treatment of autoimmune diseases such as, for example, multiple sclerosis, uveitis, arthritis, Type I insulin-dependent diabetes, Hashimoto's thyroiditis, Grave's thyroiditis, autoimmune myocarditis, etc.Type: GrantFiled: September 15, 1993Date of Patent: July 4, 2000Assignee: The United States of America as represented by the Department of Health and Human ServicesInventor: Michael J. Lenardo
-
Patent number: 6083906Abstract: Methods for regulating levels of nitric oxide are disclosed. The methods utilize IL-17 receptors, which may be used in conjunction with inhibitor of IL-1 and/or TNF.Type: GrantFiled: November 26, 1997Date of Patent: July 4, 2000Assignee: Immunex CorporationInventor: Anthony B. Troutt
-
Patent number: 6071910Abstract: A therapeutic method comprising counteracting or preventing pathologies mediated by IL-5, including those characterized by eosinophil infiltration, degranulation and inflammation, by administering to a mammal in need of such therapy, one or more compounds that bind to the eosinophil sulfonylurea receptor, optionally in combination with one or more topical anesthetics and/or glucocorticoids.Type: GrantFiled: December 5, 1997Date of Patent: June 6, 2000Assignee: Mayo Foundation for Medical Education and ResearchInventors: Gerald J. Gleich, Jennifer L. Bankers-Fulbright
-
Patent number: 6063405Abstract: Sustained release compositions comprising a drug dispersed within a polymer matrix, methods of producing the same and treatments with the complex.Type: GrantFiled: January 8, 1998Date of Patent: May 16, 2000Assignee: L.A.M. Pharmaceuticals, LLCInventors: Alan Drizen, Peter Rothbart, Gary M. Nath
-
Patent number: 6063768Abstract: The present invention provides a method for the use of at least one serotype or a combination of serotypes of Botulinum neurotoxin either alone or in combination with other peptides or fusion proteins, that when administered in a safe and effective amount, antagonize and therefore decrease or block inflammation induced by the neurogenic mechanisms underlying or associated with inflammatory disorders, in particular, arthritis.Type: GrantFiled: September 4, 1997Date of Patent: May 16, 2000Inventor: Eric R. First
-
Patent number: 6046185Abstract: Steroid compounds having various oxygen substitution on the steroid nucleus are disclosed. A specific functionality present on many of the steroid compounds is oxygen substitution at both of positions 6 and 7. Thus, certain steroids have oxygen substitution at C6 and C7, and some have specific stereochemistries such as 6.alpha. and 7.beta. oxygen substitution, and an alpha hydrogen at the 5 position in addition to having 6.alpha. and 7.beta. oxygen substitution. Steroids having 3,4-epoxy functionality are also disclosed. In addition, steroids having C17 pyran and .delta.-lactone functionality, with oxygen substitution at C6 and C7, or at C15, of the steroid nucleus, are disclosed.Type: GrantFiled: July 10, 1997Date of Patent: April 4, 2000Assignees: Inflazyme Pharmaceuticals Ltd., The University of British Columbia, The University of AlbertaInventors: David L. Burgoyne, Yaping Shen, John M. Langlands, Christine Rogers, Joseph H.-L. Chau, Edward Piers, Hassan Salari
-
Patent number: 6043231Abstract: A method for treating mammals suffering from conditions associated with excess phospholipase A.sub.2 activity and/or production comprising administering to the mammal an effective amount of a non-antimicrobial tetracycline sufficient to inhibit excess phospholipase A.sub.2 activity and/or production is disclosed. A pharmaceutical composition is also disclosed.Type: GrantFiled: August 31, 1993Date of Patent: March 28, 2000Assignee: The Research Foundation of State Univ. of New YorkInventors: Waldemar Pruzanski, Lorne M. Golub, Peter Vadas, Robert A. Greenwald, Nangavarum S. Ramamurthy, Thomas F. McNamara
-
Patent number: 6043236Abstract: Compounds of the formula I ##STR1## a process for their preparation, their use in the treatment of autoimmune disorders as well as new intermediates for their preparation.Type: GrantFiled: April 23, 1997Date of Patent: March 28, 2000Assignee: Astra AktiebolagInventors: Ralph Brattsand, Rikard Holmdahl, Liselotte Jansson, Marjana Loncar, Lars Pettersson
-
Patent number: 6037361Abstract: Fluorinated butyric acid compounds and derivatives are described as well as acid methods for the preparation and pharmaceutical compositions of same, which are useful as inhibitors of matrix metalloproteinases, particularly gelatinase A (72 kD gelatinase) and stromelysin-1, and also collagenase, matrilysin, and MMP-13, and for the treatment of multiple sclerosis, atherosclerotic plaque rupture, aortic aneurism, heart failure, restenosis, periodontal disease, corneal ulceration, treatment of burns, decubital ulcers, wound healing, cancer, inflammation, pain, arthritis, or other autoimmune or inflammatory disorders dependent upon tissue invasion by leukocytes or other activated migrating cells, acute and chronic neurodegenerative disorders including stroke, head trauma, spinal cord injury, Alzheimer's disease, amyotrophic lateral sclerosis, cerebral amyloid angiopathy, AIDS, Parkinson's disease, Huntington's disease, prion diseases, myasthenia gravis, and Duchenne's muscular dystrophy.Type: GrantFiled: March 9, 1998Date of Patent: March 14, 2000Assignee: Warner-Lambert CompanyInventors: Bruce David Roth, Patrick Michael O'Brien, Drago Robert Sliskovic
-
Patent number: 6028060Abstract: A method of treating a chronic inflammatory disease such as rheumatoid arthritis or psoriasis includes treating a patient with a toxin derived from Group B .beta.-hemolytic Streptococcus bacteria. The purified GBS toxin, or CM101, may be administered intravenously to the patient in repeated doses.Type: GrantFiled: January 29, 1997Date of Patent: February 22, 2000Assignee: Vanderbilt UniversityInventors: Carl G. Hellerqvist, Barbara D. Wamil
-
Patent number: 6028110Abstract: A pharmaceutical or veterinary composition comprising a compound of formula I ##STR1## wherein X is a --CO.sub.2 H group and R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.5 are as defined in the specification, or a salt, hydrate or solvate thereof, and a pharmaceutically or veterinarily acceptable excipient or carrier. A method of treatment of diseases or conditions mediated by MMPs in mammals, such as rheumatoid arthritis, osteoarthritis, periodontitis, gingivitis, corneal ulceration or tumour invasion by secondary means, by administering to the mammal an effective amount of the composition.Type: GrantFiled: November 22, 1996Date of Patent: February 22, 2000Assignee: British Biotech Pharmaceuticals Ltd.Inventors: Andrew Miller, Raymond Paul Beckett, Fionna Mitchell Martin, Mark Whittaker
-
Patent number: 6024960Abstract: A formulation having a rose hip concentrate is used to treat and/or alleviate the symptoms associated with inflammation including arthritis or to prevent development of arthritis. The rose hip concentrate has a high vitamin content relative to conventionally dried material, and is shown, in vitro, to inhibit the chemotaxis and oxidative burst response of human peripheral blood inflammatory cells, as well as the chemotaxis of monocytes. The formulation, in vivo, was found to inhibit chemotaxis of human peripheral blood inflammatory cells and to reduce the level of C-reactive protein, to alleviate pain and reduce inflammation in patients with arthritis.Type: GrantFiled: April 17, 1998Date of Patent: February 15, 2000Assignee: Otto Torbjorn Hansen and Marianne HansenInventors: Arsalan Kharazmi, Kaj Winther, Eydbj.o slashed.rg Rein
-
Patent number: 6019971Abstract: The invention is directed to a method of treating a T cell-mediated autoimmune disease in animals, including humans, by the oral administration of autoantigens, fragments of autoantigens, or analogs structurally related to those autoantigens, which are specific for the particular autoimmune disease. The method of the invention includes both prophylactic and therapeutic measures.Type: GrantFiled: June 5, 1995Date of Patent: February 1, 2000Assignee: AutoImmune Inc.Inventors: Howard L. Weiner, David A. Hafler
-
Patent number: 6020323Abstract: Substances comprising disaccharides and substances comprising carboxylated and/or sulfated oligosaccharides in substantially purified form, and methods of using same, are disclosed for the regulation of cytokine activity in a host. For instance, the secretion of active Tumor Necrosis Factor Alpha (TNF-.alpha.) can be either inhibited or augmented selectively by administration to the host of an effective amount of a substance of the invention. Thus, the present invention also relates to pharmaceutical compositions and their use for the prevention and/or treatment of pathological processes involving the induction of active cytokine secretion, such as TNF-.alpha.. The invention also relates to the initiation of a desirable immune system-related response by the host to the presence of activators, including pathogens. The substances and pharmaceutical compositions of the present invention may be administered daily, at very low effective doses, typically below 0.Type: GrantFiled: June 7, 1995Date of Patent: February 1, 2000Assignee: Yeda Research and Development Co. Ltd.Inventors: Irun R. Cohen, Ofer Lider, Liora Cahalon, Oded Shoseyov, Raanan Margalit
-
Patent number: 6013674Abstract: This invention provides novel indenone derivatives, their pharmaceutical formulations and their use for the inhibition of leukocyte adherence to cells.Type: GrantFiled: May 1, 1998Date of Patent: January 11, 2000Assignee: Eli Lilly and CompanyInventors: John Michael Morin, Jr., Michael Dean Kinnick, Robert Theodore Vasileff, William Thomas Jackson
-
Patent number: 6010722Abstract: Oral drugs and functional foods of the present invention contain type-II collagen denatured (fragmented) under specific conditions. Rheumatoid arthritis (RA) has been considered to be an autoimmune disease against type-II collagen as an antigen. Since denatured type-II collagen of the invention induces high oral immune tolerance and inhibits immune responses against type-II collagen, it can prevent and treat RA. Particularly, RA can effectively be prevented and treated by simple oral administration of type-II collagen.Type: GrantFiled: May 18, 1998Date of Patent: January 4, 2000Assignee: Nippon Meat Packers, Inc.Inventors: Takashi Matsumoto, Yasuki Taguchi, Kotaro Fujita, Akio Ametani, Syuichi Kaminogawa, Masayo Nakagami
-
Patent number: 6007821Abstract: The invention relates to methods and compositions for the treatment of autoimmune disease. Specifically, compositions comprising heat shock proteins, including gp96, hsp90, and hsp70, are disclosed. Immunotherapeutic methods for administering the hsp-containing compositions are disclosed. Furthermore, methods for preventing rejection of organs transplanted to treat autoimmune disease are disclosed. The disclosed methods are useful for treating a variety of autoimmune diseases, including insulin dependent diabetes mellitus.Type: GrantFiled: October 16, 1997Date of Patent: December 28, 1999Assignee: Fordham UniversityInventors: Pramod K. Srivastava, Rajiv Y. Chandawarkar
-
Patent number: 6001881Abstract: Benzoylguanidines of the formula I ##STR1## in which: R(1) to R(4) have the meanings given in the claims, are antiarrhythmic pharmaceuticals, having a cardioprotective component, which are also valuable for the prevention of ischemically induced damage, in particular in association with the triggering of ischemically induced cardiac arrhythmias. As a consequence of inhibiting the cellular Na.sup.+ /H.sup.+ exchange mechanism, they are used for treating acute or chronic damage triggered by ischemia. In addition to this, they are notable for their strong inhibitory effect on the proliferation of cells. They are suitable for preventing the genesis of high blood pressure.Type: GrantFiled: June 4, 1997Date of Patent: December 14, 1999Assignee: Hoechst AktiengesellschaftInventors: Andreas Weichert, Joachim Brendel, Heinz-Werner Kleemann, Hans Jochen Lang, Jan-Robert Schwark, Udo Albus, Wolfgang Scholz
-
Patent number: 5998457Abstract: The present invention relates to the use of creatine compounds for treating or preventing a metabolic disorder related to body weight control such as obesity, and it's associated diseases in a patient experiencing said disorder. The creatine compounds which can be used in the present method include (1) analogues of creatine which can act as substrates or substrate analogues for the enzyme creatine kinase; (2) compounds which can act as inhibitors of creatine kinase; (3) compounds which can modulate the creatine transporter (4) N-phosphocreatine analogues bearing transferable or non-transferable moieties which mimic the N-phosphoryl group. (5) compounds which modify the association of creatine kinase with other cellular components.Type: GrantFiled: October 25, 1996Date of Patent: December 7, 1999Assignee: Avicena Group, Inc.Inventor: Rima Kaddurah-Daouk
-
Patent number: 5998390Abstract: Tissue-destructive conditions related to excess proteinase activity in a biological system are treated or prevented by administering to the system a composition which combines a tetracycline and a bisphosphonate in synergistic proteinase inhibiting amounts.Type: GrantFiled: September 28, 1998Date of Patent: December 7, 1999Assignee: The Research Foundation of State University of New YorkInventors: Nungavarm S. Ramamurthy, Lorne M. Golub, Timo A. Sorsa, Olli P. Teronen, Tuula A. Salo
-
Patent number: 5994341Abstract: The present invention provides compositions comprising an anti-angiogenic factor, and a polymeric carrier. Representative examples of anti-angiogenic factors include Anti-Invasive Factor, Retinoic acids and derivatives thereof, and paclitaxel. Also provided are methods for embolizing blood vessels, and eliminating biliary, urethral, esophageal, and tracheal/bronchial obstructions.Type: GrantFiled: June 7, 1995Date of Patent: November 30, 1999Assignee: Angiogenesis Technologies, Inc.Inventors: William L. Hunter, Lindsay S. Machan, A. Larry Arsenault
-
Patent number: 5985863Abstract: The present invention relates to methods and pharmaceutical compositions for decreasing the production of interferon-gamma inducing factor (IGIF). The invention also relates to methods and pharmaceutical compositions for decreasing the production of interferon-gamma (IFN-.gamma.). The compositions comprise a therapeutically effective amount of a compound which inhibits interleukin-1.beta. converting enzyme (ICE) and a pharmaceutically acceptable carrier. The methods comprise the step of administering the above compositions to a subject. The present invention also relates to methods for treating or reducing the advancement, severity or effects of an IGIF- or IFN-.gamma.-mediated inflammatory, infectious or autoimmune condition.Type: GrantFiled: September 12, 1996Date of Patent: November 16, 1999Assignee: Vertex Pharmaceuticals, Inc.Inventors: Michael Su, Yong Gu, David J. Livingston
-
Patent number: 5968519Abstract: Method for the treatment of inflammation and pain associated with inflammatory dermatoses, gingivitis and acute injury with a composition of finely divided powder of safflower seed or its extract contained in a pharmaceutically acceptable carrier.Type: GrantFiled: May 15, 1998Date of Patent: October 19, 1999Inventors: Parvin Youssefyeh, Ronit Y. Arginteanu
-
Patent number: 5958418Abstract: The present invention relates to a natural herbal composition of effective amounts of Aloe Vera, Capsicum, Golden Seal, Comfrey Root and water, to its method of use for external application to affected parts of the body for eliminating muscular pain and to its method of preparation.Type: GrantFiled: January 22, 1997Date of Patent: September 28, 1999Inventor: Kathleen O. Johnson Prillerman
-
Patent number: 5951973Abstract: A method of treating rheumatoid arthritis comprising administering human Interleukin-4 (IL-4) to an individual afflicted with the disease. The IL-4 is administered with a pharmaceutically acceptable carrier in a dose ranging from 1 .mu.g to 100 mg.Type: GrantFiled: June 6, 1995Date of Patent: September 14, 1999Assignee: Schering CorporationInventors: Frank Lee, Takashi Yokota, Ken-ichi Arai, Timothy Mosmann, Donna Rennick
-
Patent number: 5948766Abstract: Tasteless, hydrolyzed collagen from gelatin, gelatin or animal collagenic connective tissue having an average molecular weight of from 1 to 40 kD for the preparation of agents for the treatment of osteoporosis. It may be combined with conventional agents for combatting osteoporosis, such as calcitonin, calcium salts, and/or progesterone.Type: GrantFiled: April 25, 1997Date of Patent: September 7, 1999Assignee: DGF Stoess AGInventors: Adam Milan, Bernd Eggersgluss, Klaus Braumer, Reinhard Schrieber
-
Patent number: 5942534Abstract: A method of treating a patient who has osteoarthritic disease by administering a therapeutic composition containing a photoactivatable compound, or a precursor thereof, and administering light of a photoactivating wavelength that activates the compound.Type: GrantFiled: October 10, 1997Date of Patent: August 24, 1999Assignee: The General Hospital CorporationInventors: Kenneth Trauner, Tayyaba Hasan
-
Patent number: 5932595Abstract: The present invention relates to compounds of Formula I: ##STR1## that are matrix metalloprotease inhibitors, pharmaceutical compositions containing them, methods for their use and methods of preparing these compounds.Type: GrantFiled: December 18, 1996Date of Patent: August 3, 1999Assignees: Syntex (U.S.A.) Inc., Agouron Pharmaceuticals, Inc.Inventors: Steven Lee Bender, Chris Allen Broka, Jeffrey Allen Campbell, Arlindo Lucas Castelhano, Lawrence Emerson Fisher, Robert Than Hendricks, Keshab Sarma
-
Patent number: 5929076Abstract: Novel 1,4,5-substituted imidazole compounds and compositions for use in therapy.Type: GrantFiled: October 29, 1998Date of Patent: July 27, 1999Assignee: SmithKline Beecham CorporationInventors: Jerry L. Adams, Ravi S. Garigipati
-
Patent number: 5912266Abstract: This invention concerns compositions and methods utilizing a compound of the formula: ##STR1## for reducing or controlling inflammation and treating pathological conditions mediated by intercellular adhesion. More particularly, the present invention concerns compositions and methods for blocking or modulating the function of the Beta.sub.2 Integrin family of cell adhesion molecules.Type: GrantFiled: August 13, 1997Date of Patent: June 15, 1999Assignee: American Home Products CorporationInventor: Mary Shirley Perez
-
Patent number: 5912232Abstract: Polypeptides derived from human interleukin-8 (IL-8) or other alpha chemokines which act as anti-inflammatory agents for the therapy of autoimmune disease, inflammatory conditions, and various chronic inflammatory diseases such as rheumatoid arthritis and psoriasis.Type: GrantFiled: June 28, 1996Date of Patent: June 15, 1999Assignee: Board of Regents of the University of NebraskaInventor: James E. Talmadge
-
Patent number: 5908848Abstract: The invention relates to the use of a non-steroidal anti-inflammatory drug together with an opioid analgesic in the manufacture of a medicament for the treatment of arthritis.Type: GrantFiled: May 12, 1997Date of Patent: June 1, 1999Assignee: Euro-Celtique, S.A.Inventors: Ronald Brown Miller, Stephen Gordon Douglas, Allan John Miller
-
Patent number: 5908628Abstract: The present invention provides compositions comprising talc, silkworm excrement, and ingredients of plants of species of the genera Stephania, Coix, Pinellia, Prunus, Phellodendron, Sophora, Tetrapanax, Stemona, Glycyrrhiza, Tripterygium, Forsythia and Siegesbeckia, wherein such compositions have analgesic, antipyretic, and antiinflammatory properties. The present invention also provides methods of using such compositions for treating various diseases, including osteoarthritis and rheumatoid arthritis.Type: GrantFiled: May 1, 1998Date of Patent: June 1, 1999Inventor: Liping Hou
-
Patent number: 5908861Abstract: The present invention is directed to a method for treating inflammation or inflammatory disease in an animal or mammal, which comprises the steps of administering an effective amount of an pADPRT inhibitory compound to said animal or mammal.Type: GrantFiled: May 13, 1997Date of Patent: June 1, 1999Assignee: Octamer, Inc.Inventor: Ernestt Kun
-
Methods of using low molecular weight heparins for prevention or treatment of pathological processes
Patent number: 5908837Abstract: The present invention relates to pharmaceutical compositions for the prevention and/or treatment of pathological processes involving the induction of TNF-.alpha. secretion comprising a pharmaceutically acceptable carrier and a low molecular weight heparin (LMWH). In the pharmaceutical compositions of the present invention, the LMWH is present in a low effective dose and is administered at intervals of about 5-8 days. Furthermore, the LMWH is capable of inhibiting in vitro TNF-.alpha. secretion by resting T cells and/or macrophages in response to T cell-specific antigens, mitogens, macrophage activators, disrupted extracellular matrix (dECM), laminin, fibronectin, and the like.Type: GrantFiled: November 7, 1997Date of Patent: June 1, 1999Assignee: Yeda Research and Development Co. Ltd.Inventors: Irun R. Cohen, Ofer Lider, Rami Hershkoviz -
Patent number: 5902793Abstract: This invention is directed to a method for stimulating, the proliferation of V.gamma.2V.delta.2 T cells comprising contacting V.gamma.2V.delta.2 T cells with a V.gamma.2V.delta.2 T cell proliferation stimulating amount of a compound selected from the group-consisting of a monoalkyl phosphate, a hydroxy monoalkyl phosphate, a carboxy monoalkyl phosphate, a monoalkyl pyrophosphate, an alkenyl pyrophosphate, a .gamma.-monoalkyl nucleoside triphosphate, a .gamma.-monoalkyl deoxnucleoside triphosphate, a .gamma.-alkenyl nucleoside triphosphate, and a .gamma.-alkenyl deoxynucleoside triphosphate.Type: GrantFiled: June 16, 1997Date of Patent: May 11, 1999Assignee: Albert Einstein College of Medicine of Yeshiva UniversityInventors: Barry R. Bloom, Yoshimasa Tanaka, Shigetoshi Sano
-
Patent number: 5898033Abstract: An anti-inflammatory conjugate including a polyamino acid backbone, a non-steroidal anti-inflammatory agent, and a moiety linking the anti-inflammatory agent to the backbone, wherein the polyamino acid backbone has a molecular weight greater than 250 kD.Type: GrantFiled: December 19, 1997Date of Patent: April 27, 1999Inventors: Joel K. Swadesh, Martin Sevoian
-
Patent number: 5897880Abstract: Topical gelled compositions comprising an optional drug dispersed within a polymer matrix, methods of producing the same and treatments with the complex.Type: GrantFiled: February 6, 1997Date of Patent: April 27, 1999Assignee: Lam Pharmaceuticals, LLC.Inventors: Alan Drizen, Peter Rothbart, Gary M. Nath
-
Patent number: 5894019Abstract: A topically applicable pharmaceutical composition comprises at least one liquid lipid, at least one pharmaceutical active ingredient which is soluble in at least one of the liquid lipids and is re-absorbed by the skin, and a hydrous gel which is the main component of the composition, whereby at least one lipid and at least one active ingredient are worked into the gel and the composition is essentially free of emulsifying agents and solid constituents, with the exception of the necessary gelatinizing agent required to form the hydrous gel. All of the active ingredients are present in dissolved form, whereby at least one active ingredient is dissolved in the liquid lipid, and this lipid containing the dissolved active ingredient is itself the internal phase and is worked into the hydrous gel as the external phase. The composition is also essentially free of surface-active substances.Type: GrantFiled: September 17, 1997Date of Patent: April 13, 1999Assignee: GEBRO Broschek Gesellschaft m.b.H.Inventors: Ernst Hesse, Gerhard Hantich, Volker Eisenreich, Torsten Moller
-
Patent number: 5889048Abstract: A pharmaceutical formulation having immunomodulating and regenerating effect on abnormal function of cell tissue division-regulating system comprises, as an active ingredient, mercury dichloride or potassium arsenite or sodium arsenate in the amount of 0.01-1.5% by weight and of a diluent up to 100% by weight. The proposed pharmaceutical formulation preferably contains natural white grape wine with sugar content of 3-4% by weight or whey with sugar content of 3-4% by weight as the diluent.Type: GrantFiled: August 19, 1996Date of Patent: March 30, 1999Inventor: Tamara Vasilievna Vorobieva
-
Patent number: 5885597Abstract: Disclosed is a topical composition for relieving pain in a person in need of such relief, consisting essentially of an effective amount of a combination of at least one corticoid analgesic, at least one arylpropionic acid type analgesic, and at least one p-aminobenzoic acid ester type local anesthetic; an amount effective in enhancing the effectiveness in relieving pain of the combination of capsaicin, and an amount effective to increase the transmission thereof of through the skin of at least one phospholipid and at least one polyoxyethylenepolyoxypropylene copolymer.Type: GrantFiled: October 1, 1997Date of Patent: March 23, 1999Assignee: Medical Research Industries,Inc.Inventors: Jonah Botknecht, Robert Fishman
-
Patent number: 5882678Abstract: This invention provides an interdigitation-fusion liposome comprising an arachidonic acid metabolite, a lipid bilayer comprising a lipid and an aqueous compartment comprising a release-inhibiting buffer. Preferred arachidonic acid metabolites are the prostaglandins, particularly PGE.sub.1. The liposomal formulations can be used to treat animals, particularly humans, for diseases, disorders or conditions which can be ameliorated by prostaglandins, e.g., cell activation/adhesion disorders and inflammatory disorders.Type: GrantFiled: November 15, 1994Date of Patent: March 16, 1999Assignee: The Liposome Co, Inc.Inventors: Andrew S. Janoff, Sharma R. Minchey
-
Patent number: 5883132Abstract: The present invention relates to compounds selected from the group consisting of:(i) the compounds of the formula ##STR1## in which: R is a hydrogen atom, a group OH, a group OCH.sub.3 or a group CH.sub.2 OH,*C, in the case where R is not a hydrogen atom, is an asymmetric carbon atom of (R,S), (R) or (S) configuration, and**C is an asymmetric carbon atom of (R,S) or (R) configuration; and(ii) their addition salts.It further relates to the method of preparing these compounds, to their use in therapeutics and in the field of analysis, and to intermediates.Type: GrantFiled: October 10, 1996Date of Patent: March 16, 1999Assignee: Fournier Industrie Et SanteInventors: Luc Lebreton, Patrice Renaut, Philippe Durand
-
Patent number: 5880101Abstract: The present invention relates to the use of at least one polyene macrolide for the preparation of pharmaceutical compositions for the treatment of diseases that are associated with an impaired energy turnover. Particularly, the present inventions allows to specifically stimulate the energy conversion in human cell, i.e. to stimulate the cell metabolism, and thus to treat or prevent a series of diseases.Type: GrantFiled: February 27, 1997Date of Patent: March 9, 1999Assignee: Dr. Zerle GmbHInventor: Georgi Stankov
-
Patent number: 5876762Abstract: The invention concerns fractions from echinoderms of the class Holothuroidea (sea cucumber) that can be used directly as active therapeutic agents or as raw materials in producing biologically active derivatives thereof. The fractions can be used alone or in combination and are derived from a) the epithelial layer, free of muscle and collagenous tissues, b) the isolated flower, or c) the whole body wall substantially free muscle, viscera and flower. The invention also concerns processes for obtaining these fractions that involve the use of thermal/mechanical and/or enzymatic means.Type: GrantFiled: August 5, 1996Date of Patent: March 2, 1999Assignee: Coastside Bio ResourcesInventor: Peter Donald Collin